Background: Survival of patients with cT4 esophageal cancer is dismal. Although the
| INTRODUC TI ON
Esophageal cancers tend to invade adjacent organs, including the trachea, bronchus, lung, and aorta, as a result of the lack of serosa in the esophagus and the fact that this conduit is located in a very narrow mediastinal space. 1, 2 Tumors that invade adjacent organs are classified as T4, according to the TNM staging system of the International Union against Cancer (UICC). Despite recent advances in multidisciplinary treatments, the prognosis of patients with T4
esophageal cancer remains unsatisfactory. 3 Although esophageal cancer is associated with a high incidence of morbidity and mortality, treating with surgery alone, where neighboring organs are resected together with an esophagectomy, has not improved survival. [4] [5] [6] [7] Similarly, definitive chemoradiation (dCRT), a maximum-dose irradiation together with chemotherapy used as a curative treatment which many investigators consider the most suitable treatment for T4 esophageal cancer, has not dramatically contributed to improving patient survival. 8 As a result of a paucity of evidence, a treatment strategy for T4 esophageal cancer has not been established to date. According to the Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus, 2017, the current standard chemotherapeutic regimen for treating esophageal cancer is 5-fluorouracil (5-FU) combined with cisplatin 9 (CF) because of their synergistic radiosensitizing effects. 10 Previous studies have reported that concurrent CRT with a CF regimen was effective for treating advanced esophageal cancers, including T4 tumors. 1, 11 Thus, two modalities are currently in use for the treatment of cT4 esophageal tumors: 12, 13 dCRT [14] [15] [16] [17] [18] [19] and induction chemotherapy or CRT, followed by conversion surgery (CS). 12, 13, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Theoretically, when surgery completely removes the tumor, survival should be prolonged, regardless of the T stage. Thus, effective induction treatments must be established for T4 tumors to achieve curative resections, even for initially unresectable tumors. 30 However, to our knowledge, there is little or no information on the differences in clinical outcome between patients with T4 esophageal tumors treated with dCRT and those eventually treated with CS.
Recently, new triplet chemotherapy regimens have been reported to yield high response rates for esophageal squamous cell carcinoma (ESCC). 31, 32 In particular, docetaxel plus CF (DCF) was shown to be more effective for treating ESCC than the standard treatment of CF or CF plus adriamycin (ACF). 31 Some studies showed promising results when induction chemotherapy with the DCF regimen was applied before carrying out CS for cT4 ESCC. 20, 24, 30 In the present review, we focus on these treatments and the outcomes in patients with T4 esophageal cancer, and we discuss future perspectives regarding these modalities.
| MATERIAL S AND ME THODS
We conducted a systematic search of the scientific literature on PubMed/MEDLINE to obtain all relevant articles involving T4 esophageal cancers published up to July 2018. In the searches, we excluded all non-English articles. To avoid duplications of data, articles from the same unit or hospital were included only once, when data were being updated in a later publication. The search terms were "T4 esophageal cancer," "invading (involving) adjacent organ," "definitive chemoradiation," "induction therapy," "salvage surgery,"
and "conversion surgery." All available major publications (primarily from high-volume surgical centers) were considered. Articles were selected when the abstract indicated that data were collected on patients with T4 esophageal cancer included in randomized controlled trials (RCT), other cohorts, or comparative studies. We also reviewed the reference lists of these articles to find additional candidate studies. For the present study, data were taken from the published reports; authors were not contacted to obtain additional information.
Therefore, articles that lacked necessary data, including survival information according to each treatment group, were excluded from this systematic review. Reports with fewer than 10 cases were also excluded from this study.
| RE SULTS

| Studies included in the present review
A fiow chart of the article selection process is shown in Figure S1 .
A total of 28 articles regarding dCRT or/and induction treatment, followed by CS for cT4 esophageal cancer were finally selected (Table 1) .
| Definitive chemoradiation
| Chemoradiation regimen
As summarized in Tables 1 and 2, a total of 16 Concurrent radiotherapy was applied in all studies, with a total external radiation dose of 50-66 Gy.
| Adverse effects, morbidity, and mortality
The most common early adverse effects associated with dCRT were hematotoxicities, including leukocytopenia, neutropenia, and thrombocytopenia (Table 2 ). In contrast, esophagitis, anorexia, oral mucositis, and esophageal dysphagia were common non-hematological toxicities (Table 2) . Fistula formation, including esophagotracheal (bronchial or pulmonary) and esophagoaortic fistulas, was observed in 9%-22% 16, 18, 19, [33] [34] [35] [36] [37] 39 
| Response to dCRT and patient survival
We found that patients with T4 tumors experienced a clinical complete response (cCR) of 0%-39% and an overall response rate (both complete and partial responses) of 57%-88% (Table 2) . [16] [17] [18] [19] 33, [35] [36] [37] [38] [39] [40] In contrast, the 1-, 3-, and 5-year overall survival (OS) rates of patients with T4 esophageal cancer that received dCRT were 26%-79%, 0%-44%, and 0%-14%, respectively. [12] [13] [14] [15] [16] [17] [18] [19] [33] [34] [35] [36] [37] [38] 40 Seto et al 12 examined prognosis according to the response to CRT; they reported that the 1-, 3-, and 5-year survival rates of patients that experienced cCR and non-cCR were 83%, 33%, 33%, and 23%, 0%, 0%, respectively. Itoh et al 17 also reported that patients that achieved cCR had a significantly better prognosis than those with non-cCR (1-, 3-, 5-year OS rates: 83%, 25%, 25% vs 26%, 7%, 0%; P = 0.0317). In a phase I/II study of DCF with concurrent radiation (60 Gy), Miyazaki et al 35 reported that the CR rate and overall response rate were 48% and 86%, respectively, in patients with cT4 esophageal cancer. Accordingly, the prognosis of patients with T4 esophageal cancer that received dCRT depends on whether cCR can be achieved. However, patients that achieved cCR after dCRT sometimes developed disease recurrence. Therefore, careful follow up is necessary, even after achieving cCR. In addition, for recurrence or persistent disease after cCR, salvage surgery or palliation may be indicated, depending on the clinical situation and the patient's general condition.
| Conversion surgery following induction treatments
| Regimen
As shown in Tables 1 and 3, 14 In all studies, the combination of CF with concurrent 36-60 Gy irradiation was the most common regimen used as primary treatment. 12, 13, [20] [21] [22] [25] [26] [27] [28] [29] 41, 42 All CRT in these series were carried out as a "planned" treatment before surgical resection; therefore, after induction treatment, the indication for CS was the relief of T4 invasion
The interval between the completion of CRT and CS was 3-8 weeks in all studies with available related data (Table 3) . 13, [20] [21] [22] 24, 26, 27, 29, 42 Alternatively, some more recent studies applied triplet chemotherapy regimens, including DCF, ACF, 20, 24 and the combination of 5-FU, adriamycin, and nedaplatin (FAN). 
| Resection and curative resection rates
Intention-to-treat (ITT) analysis showed that the rates of resection and curative resection (R0) for T4 diseases ranged from 26% to 100%
and from 32% to 96%, respectively (Table 3) . 13, [20] [21] [22] [23] [24] [25] [27] [28] [29] 41, 42 Seto et al 12 analyzed data for 59 patients with cT4 that underwent CS; they reported that 10 (17%), six (10%), and six (10%) patients underwent combined resections of the major respiratory tract, lung, or pericardium, respectively. However, no combination resection was used in the other studies (Table 3) . Although Pimiento et al 23 reported a curative resection rate of 96% after induction CRT, the most commonly invaded organ in that study was the pleura (75.6%), which was categorized as cT4a, but not cT4b, based on the UICC classification.
| Perioperative morbidity and mortality
Ranges of perioperative morbidity and mortality rates were 29%-87% and 0%-21%, 12, 13, [20] [21] [22] [23] 25, [27] [28] [29] 42 respectively. Fujita et al observed, but perioperative complications occurred, including recurrent laryngeal nerve palsy (38%), pleural effusion (24%), and lung infection (14%). Grade 3 severity rates were 5% for recurrent laryngeal nerve palsy, 5% for lung infections, 5% for wound infections, 5% for pulmonary fistulas, and 5% for dysphagia, but all of these complications were manageable. No grade 4 complications were observed; thus, there was no mortality and no serious complications related to surgery.
| Tumor response and survival
We found that 20%-100% of patients with T4 esophageal cancer that received CS achieved a clinical response to induction CRT or chemotherapy (Table 3) . 12 T4 patients that underwent CS were 24%-100%, 5%-50%, and 0%-51%, respectively. 12, 13, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] 41, 42 Among the five studies 23, 26, 27, 29, 42 that classified prognosis according to the pathological response to CRT, 1-, 3-, and 5-year OS rates were 85%-100%, 61%-100%, and 25%-86%, respectively, for grade 3 tumors, and 20-65%, 0-35%, and 0%-30% for grade 0-2 tumors (Table 3) .
Miyata et al 24 analyzed 98 patients that underwent CRT or triplet chemotherapy plus CRT, with or without subsequent CS; they found that patients that underwent CS had significantly more favorable 3-and 5-year OS rates (48% and 40%, respectively) compared to patients that did not receive CS (7% and 4%, respectively). This trend was also identified in patients that showed a good response to induction treatments and those that showed a poor response using separately analyzed survival data (data not shown). Seto et al and 0 months, respectively. 25 Furthermore, median survival times were 22.3 and 9 months for patients with R0 and R1/2 resections, respectively (P < 0.001). The recurrence pattern after a CS for cT4 esophageal cancer was only described in one study by Yano et al 29 They reported that, among 27 patients, 17 (63%) experienced recurrence after a curative resection; among these 17 recurrences, eight were local, six were distant, two were local plus distant, and one displayed an unknown.
| Triplet chemotherapy as an initial induction treatment
The standard regimen for induction treatment in locally advanced T4 esophageal cancer is concurrent CRT with CF. The CF regimen has not changed in decades, but it is possible that a stronger regimen might improve outcomes. In 2007, a novel regimen of DCF achieved a significant antitumor effect and improved the outcome of patients with head and neck cancer. 44 DCF was also expected to be effective for ESCC because of its histological similarity to head and neck cancer. Indeed, DCF had a strong antitumor effect for ESCC, and it is currently being used as a first-line chemotherapy regimen for ESCC. DCF even achieved local tumor control comparable to that achieved with CRT; thus, several studies Calculated with intention-to-treat analysis.
aimed to test downstaging the tumor and, subsequently, converting to surgery as a multidisciplinary strategy for treating cT4 ESCC.
In that trial, the first-line chemotherapy regimen consisted of three courses of DCF. When resectability was achieved after the third course of DCF, CS was carried out. When resectability was not achieved by the middle evaluation of CRT, dCRT was given. That study reported that CS was carried out in 41.7% of patients, and an R0 resection was confirmed in 39.6% of patients. A point estimate of the 1-year survival rate was 67.7%, and the 80% confidence interval had a lower limit of 59.5%. Because this lower limit was higher than the 50% threshold, this first prospective trial showed a statistically positive effect. In addition, the 1-year survival rate in that study was higher than that found in the standard-dose CF-RT arm in the JCOG0303 trial. 
| SUMMARY AND PER S PEC TIVE S
A possible algorism of treatment for cT4 esophageal cancer is summarized in Figure 1 . In the case of dCRT, patient prognosis depends on whether or not cCR can be achieved. However, it is often difficult to determine a treatment strategy after achieving cCR with F I G U R E 1 Possible algorism of a treatment strategy for cT4 esophageal cancer. Different treatment strategies, including (A) definitive chemoradiation (CRT), potentially followed by salvage surgery, in the absence of a complete response (CR); or (B) induction treatments potentially followed by conversion surgery. BSC, best supportive care; DCF, docetaxel, cisplatin, and 5-fluorouracil dCRT. It is also clinically difficult to make a diagnosis of CR based on endoscopic biopsies, which sometimes give false-negative results, or imaging tools, due to CRT-induced inflammation, fibrosis, or edema. In contrast, it remains controversial whether surgery should play a role in a treatment modality carried out after achieving CR with dCRT. Two randomized trials 45, 46 have compared preoperative dCRT, followed by surgery, versus dCRT alone to assess the role of surgery in T3 and/or T4 diseases. They found that adding surgery to dCRT provided no survival benefit. Furthermore, significantly higher operative mortality rates and major morbidities, including anastomotic leaks and pulmonary complications, were reported in both trials. These findings were presumably due to the adverse effects of CRT, including radiation-induced fibrosis, which affected thoracic tissue and patient performance status. Meanwhile, as patients that achieved cCR after dCRT sometimes developed disease recurrence, careful follow up is necessary even after achieving cCR.
In addition, for recurrence or persistent disease (non-CR) after cCR, Older patients are often excluded, or at least underrepresented, in clinical trials. Thus, it is reasonable to question whether the results are generally transferable to the older population. Although it is true that some older patients are not suitable for intensive multimodality treatment, age alone should not be taken as the decisive factor in making treatment decisions in T4 esophageal cancer. In fact, according to a recent analysis by Pultrum et al., 47 older age did not significantly influence the overall outcome or the complication rate in patients treated with extended esophagectomies, However, the presence of comorbidity had a significant impact on survival.
Thus, it might be more appropriate to base treatment decisions on comorbidity and/or performance status, rather than chronological age alone. 48 Although we proposed a possible treatment algorithm for cT4 esophageal cancer (Figure 1 ), the tolerance for each treatment should first be evaluated, considering comorbidity, performance status, and general condition, in addition to the patient's age.
Radiation alone or palliation might be indicated for older patients at high risk; alternatively, a potentially curative treatment strategy might be considered for carefully selected older patients without severe comorbidity.
This review has shown that CS appeared to be superior to dCRT for treating T4 esophageal cancer with respect to local control and short-term prognosis despite the relatively high association with perioperative morbidities. However, although the fistula formation rate was relatively high in dCRT, a CR to CRT might lead to a better prognosis. When more powerful chemotherapy, such as a DCF regimen, is tolerable concurrent with definitive radiation, this is the most promising option for treating T4 esophageal cancer. Also, as an initial induction therapy, triplet chemotherapy, including a DCF regimen, can yield both significant local control and systemic control, which enables the application of CS for T4 esophageal cancer, without preoperative radiation. DCF chemotherapy can also be used for chemoselection, followed by CS or dCRT, as a multidisciplinary treatment strategy. In addition, a number of clinical trials are currently testing immune-checkpoint inhibitors with/without chemotherapy or radiation. These treatments might become viable treatment options for T4 esophageal cancer in the near future. Randomized controlled trials that include a large population are needed to define a standard treatment for T4 esophageal cancer.
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